Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

Germany’s Merck KGaA has agreed to buy SpringWorks Therapeutics, adding the US biotech’s portfolio of cancer and rare disease ...

Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...

FRANKFURT (REUTERS) -German healthcare and materials group Merck KGaA said on Monday it struck a deal to acquire U.S. biotech ...

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion. The acquisition – which was confirmed to be in the final stages ...

Drugmaker Merck said Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it prepares to deal with President Trump’s tariffs. The new facility will produce ...

Merck (NYSE: MRK) recently announced its first-quarter results, exceeding Wall Street’s expectations for both earnings and revenue. The company reported revenues of $15.53 billion and adjusted ...

(Reuters) -U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it prepares to deal with President Donald Trump's tariffs.

She regularly appears on CBS News 24/7 to discuss her reporting. Merck is investing $1 billion to build a U.S. plant in Delaware, in a show of its commitment to domestic manufacturing. The move ...

Seven weeks after opening a new $1 billion vaccine manufacturing facility in North Carolina, Merck has revealed that it is breaking ground on another $1 billion plant—this one in Wilmington ...